AGIO - NASDAQ
Agios Pharmaceuticals, Inc.
$27.68
-1.1%Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotagio
Research Development Expenses
Last Annual Value
334.36M
3-Year CAGR
6%
5-Year CAGR
10%
10-Year CAGR
9%
Agios Pharmaceuticals, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 334.36M | 5.0% | 5.4% | 4.3% | |
 Beam Therapeutics Inc. NASDAQ:BEAM | 409.62M | -2.2% | 1.1% | N/A | |
 Cogent Biosciences, Inc. NASDAQ:COGT | 269.78M | 15.8% | 37.0% | 28.5% | |
 Sarepta Therapeutics, Inc. NASDAQ:SRPT | 1.52B | 20.2% | 14.6% | 23.2% | |
 89bio, Inc. NASDAQ:ETNB | 345.04M | 41.3% | 37.5% | N/A | |
 ImmunityBio, Inc. NASDAQ:IBRX | 207.88M | -3.6% | 1.2% | 22.9% | |
 Liquidia Corporation NASDAQ:LQDA | 39.28M | -3.2% | 13.9% | 5.4% | |
 Denali Therapeutics Inc. NASDAQ:DNLI | 418.78M | -0.4% | 9.6% | 18.7% | |
 Arcus Biosciences, Inc. NYSE:RCUS | 523.00M | 15.4% | 15.3% | 43.4% | |
 Recursion Pharmaceuticals, Inc. NASDAQ:RXRX | 425.27M | 20.8% | 25.7% | N/A |
Agios Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your AGIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.